No quarterly revenue total was found in MINERALYS THERAPEUTICS, INC.'s SEC filings.
Mineralys Therapeutics, Inc. (MLYS) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Sep 30, 2026 it held $101.3 million in cash and investments and $100,000 in total debt.
Revenue
—
Net income
$-57.33M
-55.2% vs year-ago quarter
Operating cash flow
$-43.10M
-49.3% vs year-ago quarter
Free cash flow
$-37.90M
+43.3% vs year-ago quarter
EPS
$-0.64
-23.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
88.56M
+11.9% vs year-ago quarter
Net cash
$101.17M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MLYS (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Radnor, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1933414
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$60.1M | -$246.0M | -$45.3M | -$38.3M | -$41.1M |
| Net income | -$57.3M | -$241.1M | -$39.3M | -$32.2M | -$36.9M |
| Diluted EPS | -$0.64 | -$2.85 | -$0.47 | -$0.40 | -$0.52 |
| Operating cash flow | -$43.1M | -$32.6M | -$39.5M | -$37.9M | -$28.9M |
| Free cash flow | — | — | — | -$37.9M | -$28.9M |
| Total assets | $630.1M | $667.9M | $652.9M | $661.8M | $599.9M |
| Total liabilities | $126.3M | $116.9M | — | — | — |
| Stockholders' equity | $503.8M | $550.9M | $638.1M | $646.7M | $576.4M |
| Cash and investments | $101.3M | $138.3M | $112.8M | $172.9M | $217.6M |
| Total debt | $100,000 | $100,000 | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Nov 4, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Oct 29, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 19, 2026 | Oct 16, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Aug 11, 2026 | Aug 5, 2026 |
All 408 Mineralys Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.